


IN THE CLAIMS:

1. (Previously Amended) A compound of the formula:



wherein X is selected from the group consisting of: O, N-OR^a, N-NR^bR^c and C₁-6 alkylidene, wherein said alkylidene group is unsubstituted or substituted with a group selected from hydroxy, amino, O(C₁-4alkyl), NH(C₁-4alkyl), or N(C₁-4alkyl)₂;

R¹ is selected from the group consisting of hydrogen, C₁-6alkyl, C₂-6alkenyl, and C₂-6alkynyl, wherein said alkyl, alkenyl and alkynyl groups are either unsubstituted or substituted with a group selected from OR^c, SRC, NR^bRC, C(=O)RC, C(=O)CH₂OH, or phenyl, wherein said phenyl group can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl);

R² is selected from the group consisting of hydrogen, hydroxy, iodo, O(C=O)RC, C(=O)RC, CO₂RC, C₁-6alkyl, C₂-6alkenyl, and C₂-6alkynyl, wherein said alkyl, alkenyl and alkynyl groups are either unsubstituted or substituted with a group selected from OR^c, SRC, NR^bRC, C(=O)RC, C(=O)CH₂OH, or phenyl, wherein said phenyl group can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl); or R¹ and R², when taken together with the carbon atom to which they are attached, form a carbonyl group;

or R¹ and R², when taken together, form a C₁-6 alkylidene group, wherein said alkylidene group is either unsubstituted or substituted with a group selected from the group consisting of hydroxy, O(C₁-4alkyl), N(C₁-4alkyl)₂, and phenyl, wherein said phenyl group can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl);

R³ is selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, NR^aRC, OR^a, C(=O)R^a, CO₂RC, CONR^aRC, SR^a, S(=O)R^a, SO₂R^a, C₁-10alkyl, C₂-10alkenyl, C₂-10alkynyl, C₃-7cycloalkyl, 4-7 membered heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl groups are either unsubstituted or independently substituted with 1, 2 or 3 groups selected from fluoro, chloro, bromo, iodo, cyano, OR^a, NR^aRC, O(C=O)R^a, O(C=O)NR^aRC, NR^a(C=O)RC, NR^a(C=O)ORC, C(=O)R^a, CO₂R^a, CONR^aRC, CSNR^aRC, SR^a, S(O)R^a, SO₂R^a, SO₂NR^aRC, YR^d, and ZYR^d;

R⁴ is selected from the group consisting of hydrogen and fluoro;

R⁵ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, amino, OR^b, OR^a, O(C=O)RC, O(C=O)ORC, and NH(C=O)RC;

R⁶ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, OR^b, OR^a, O(C=O)RC, and O(C=O)ORC;

R⁷ is selected from the group consisting of hydrogen, OR^b, NR^bRC, fluoro, chloro, bromo, iodo, cyano, nitro, C₁-6alkyl, C₂-6alkenyl, CF₃, and CHF₂;

R⁸ and R⁹ are each independently selected from the group consisting of hydrogen, C₁-6alkyl, C₂-6alkenyl, and C₂-6alkynyl, or R⁸ and R⁹, when taken together with the carbon atom to which they are attached, form a 3-5 membered cycloalkyl ring, or R⁸ and R⁹, when taken together with the carbon atom to which they are attached, form a carbonyl group;

R¹⁰ is selected from the group consisting of hydrogen, C₁-10alkyl, C₂-10alkenyl, C₂-10alkynyl, C₃-6cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl groups can be optionally substituted with a group selected from chloro, bromo, iodo, OR^b, SR^b, C(=O)R^b, or 1-5 fluoro, or R¹⁰ and R¹, when taken together with the three intervening carbon atoms to which they are attached, form a 5-6 membered cycloalkyl or cycloalkenyl ring which can be optionally substituted with 1 or 2 groups selected from oxo, hydroxy, or C₁-6alkyl;

R¹¹ is selected from the group consisting of hydrogen and C₁-4alkyl;

R^a is selected from the group consisting of hydrogen, C₁-10alkyl, and phenyl, wherein said alkyl group can be optionally substituted with a group selected from hydroxy, amino, O(C₁-4alkyl), NH(C₁-4alkyl), N(C₁-4alkyl)₂, phenyl, or 1-5 fluoro, and wherein said phenyl groups can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl);

R^b is selected from the group consisting of hydrogen, C₁-10alkyl, benzyl and phenyl, wherein said phenyl group can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl);

R^c is selected from the group consisting of hydrogen, C₁-10alkyl and phenyl, wherein said phenyl group can either be unsubstituted or substituted with 1-3 substituents independently selected from the group consisting of C₁-4alkyl, OH, O(C₁-4alkyl), NH₂, NH(C₁-4alkyl), NH(C₁-4alkyl)₂, halo, CN, NO₂, CO₂H, CO₂(C₁-4alkyl), C(O)H, and C(O)(C₁-4alkyl);

C-10
cont'd

or Ra and Rc, whether or not on the same atom, can be taken together with any attached and intervening atoms to form a 4-7 membered ring;


Rd is selected from the group consisting of NrbRc, ORa, CO2Ra, O(C=O)Ra, CN, NRc(C=O)Rb, CONRaRc, SO2NRaRc, and a 4-7 membered N-heterocycloalkyl ring that can be optionally interrupted by O, S, NRc, or C=O;

Y is selected from the group consisting of CRbRc, C₂₋₆ alkylene and C₂₋₆ alkenylene, wherein said alkylene and alkenylene linkers can be optionally interrupted by O, S, or NRc;

Z is selected from the group consisting of O, S, NRc, C=O, O(C=O), (C=O)O, NRc(C=O) or (C=O)NRc;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Previously Amended) A compound of the formula:



wherein X is selected from the group consisting of O and N-ORa;

R¹ is selected from the group consisting of hydrogen and C₁₋₆alkyl, wherein said alkyl group is either unsubstituted or substituted with a group selected from ORc or C(=O)Rc;

R² is selected from the group consisting of hydrogen, hydroxy, iodo, and C₁₋₆alkyl, wherein said alkyl group is either unsubstituted or substituted with a group selected from ORc or C(=O)Rc;

R³ is selected from the group consisting of chloro, bromo, iodo, cyano, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, aryl and heteroaryl, wherein said alkyl, alkenyl, aryl and heteroaryl groups are either unsubstituted or independently substituted with 1, 2 or 3 groups selected from fluoro,

chloro, bromo, iodo, cyano, OR^a, NR^aRC, C(=O)R^a, CO₂R^c, NR^aC(=O)R^c, CONR^aRC, CSNR^aRC, SRA, YR^d, and ZYR^d;

R⁴ is selected from the group consisting of hydrogen and fluoro;

R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, fluoro, O(C=O)R^c and OR^a;

R⁷ is selected from the group consisting of hydrogen, NR^bRC, chloro, bromo, nitro and C₁₋₆alkyl;

R⁸ and R⁹ are each independently selected from the group consisting of hydrogen and C₁₋₆alkyl;

or R⁸ and R⁹, when taken together with the carbon atom to which they are attached, form a carbonyl group;

R¹⁰ is selected from the group consisting of hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₆cycloalkyl and cycloalkylalkyl, wherein said alkyl, alkenyl, cycloalkyl and cycloalkylalkyl groups can be optionally substituted with a group selected from OR^b, SR^b, C(=O)R^b, or 1-5 fluoro; or R¹⁰ and R¹, when taken together with the three intervening carbon atoms to which they are attached, form a 5-6 membered cycloalkyl ring which can be optionally substituted with C₁₋₆alkyl;

R¹¹ is selected from the group consisting of hydrogen and C₁₋₄alkyl;

R^a is selected from the group consisting of hydrogen, C₁₋₁₀alkyl, and phenyl, wherein said alkyl group can be optionally substituted with a group selected from hydroxy, amino, O(C₁₋₄alkyl), NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, phenyl, or 1-5 fluoro;

R^b is selected from the group consisting of hydrogen, C₁₋₁₀alkyl, benzyl and phenyl;

R^c is selected from the group consisting of hydrogen and C₁₋₁₀alkyl and phenyl; or R^a and R^c, whether or not on the same atom, can be taken together with any attached and intervening atoms to form a 4-7 membered ring;

R^d is selected from the group consisting of NR^bRC, OR^a, CO₂R^a, O(C=O)R^a, CN, NR^c(C=O)R^b, CONR^aRC, SO₂NR^aRC, and a 4-7 membered N-heterocycloalkyl ring that can be optionally interrupted by O, S, NR^c, or C=O;

C
Cont'd

Y is selected from the group consisting of CR^bRC, C₂₋₆ alkylene and C₂₋₆ alkenylene, wherein said alkylene and alkenylene linkers can be optionally interrupted by O, S, or NR^c;

Z is selected from the group consisting of O, S, NR^c, C=O, O(C=O), (C=O)O, NR^c(C=O) or (C=O)NR^c;
or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Previously Amended) The compound according to Claim 2, wherein X is selected from the group consisting of O, N-OH and N-OCH₃, or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Previously Amended) The compound according to Claim 3, wherein R⁶ is selected from the group consisting of OR^a and O(C=O)RC or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Previously Amended) The compound according to Claim 4, wherein R³ is selected from the group consisting of hydrogen, chloro, bromo, iodo, cyano, C₁₋₁₀alkyl, aryl and heteroaryl, wherein said alkyl, aryl and heteroaryl groups are either unsubstituted or independently substituted with 1, 2 or 3 groups selected from fluoro, chloro, bromo, cyano, NR^aRC, C(=O)R^a, CO₂RC, CONR^aRC, SR^a, YR^d, and ZYR^d, or a pharmaceutically acceptable salt or stereoisomer thereof.

*C-1
Confidential*

6. (Previously Amended) The compound according to Claim 1 selected from the group consisting of:

4-bromo-7-hydroxy-9a-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one;

9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one;

(3E)-9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one oxime;

9a-[(1E)-1-butenyl]-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one;

4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
4-bromo-9a-butyl-3-methylene-2,3,9,9a-tetrahydro-1*H*-fluoren-7-ol;
9a-butyl-4-cyano-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
4-benzyl-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a butyl-7-hydroxy-4-(2-thienyl)-1,2,9,9a-tetrahydro-3*H*-fluoren-3-ene;
9a-butyl-7-hydroxy-4-{4-[2-(1-piperidinyl)ethoxy]phenyl}-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;
9a-butyl-7-hydroxy-4-(4-hydroxyphenyl)-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
(2*E*)-3-[4-(9a-butyl-7-hydroxy-3-oxo-2,3,9,9a-tetrahydro-1*H*-fluoren-4-yl)phenyl]-2-propenoic acid;
9a-butyl-7-hydroxy-8-methyl-1,2,9,9a-3*H*-tetrahydro-fluoren-3-one;
4-bromo-9a-butyl-7-hydroxy-8-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a butyl-4,8-dimethyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-8-chloro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
(2*S**R*,9a*S**R*)-9a-butyl-2,4-dimethyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
(2*S**R*,9a*R**S*)-9a-butyl-2,4-dimethyl-7-hydroxy-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-7-hydroxy-2,2,4-trimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

C
Cont'd

(2*S*,9*a**RS*)-9*a*-butyl-7-hydroxy-2-iodo-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

(2*S*,9*a**RS*)-9*a*-butyl-2,7-dihydroxy-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

(2*RS*,9*a**SR*)-9*a*-butyl-7-hydroxy-2-(2-hydroxyethyl)-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

(2*SR*,9*a**SR*)-2-allyl-9*a*-butyl-7-hydroxy-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

(2*RS*,9*a**SR*)-9*a*-butyl-7-hydroxy-2-(3-hydroxy-2-oxopropyl)-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

(9*SR*,9*a**SR*)-7-hydroxy-4-methyl-9-propyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

9*a*-butyl-8-chloro-7-hydroxy-4-(trifluoromethyl)-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

4-acetyl-9*a*-butyl-8-chloro-7-hydroxy-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

9*a*-butyl-8-chloro-4-cyano-7-hydroxy-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

9*a*-butyl-4-ethyl-6-fluoro-7-hydroxy-8-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

9*a*-butyl-8-chloro-6-fluoro-7-hydroxy-4-methyl-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

9*a*-butyl-8-chloro-4-ethyl-6-fluoro-7-hydroxy-1,2,9,9*a*-tetrahydro-3*H*-fluoren-3-one;

C
Confidential

4-bromo-9a-butyl-8-chloro-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-8-chloro-6-fluoro-7-hydroxy-4-(trifluoromethyl)-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

2-hydroxy-5-methylgibba-1(10a),2,4,4b-tetraen-6-one;

4-bromo-9a-butyl-3-oxo-2,3,9,9a-1*H*-fluoren-7-yl pivalate;

7-hydroxy-4,9a-dimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

7-hydroxy-4-methyl-9a-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

7-hydroxy-9a-isobutyl-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4-ethyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-4-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4,9a-dibutyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4-chloro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-4-iodo-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-4-trifluoromethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-4-phenyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4-(2-furyl)-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

C
Confidential

7-hydroxy-9a-(3-iodopropyl)-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

7-hydroxy-4-methyl-9a-(2-methyl-1-propenyl)-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4-{4-[2-(dimethylamino)ethoxy]phenyl}-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

9a-butyl-4-{4-[2-(diethylamino)ethoxy]-phenyl}-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

9a-butyl-7-hydroxy-4-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

9a-butyl-7-hydroxy-4-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

9a-butyl-4-{4-[3-(dimethylamino)propoxy]-phenyl}-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

9a-butyl-7-hydroxy-4-{4-[3-(1-piperidinyl)propoxy]phenyl}-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one hydrochloride;

(3*E*)-9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one *O*-methyloxime;

(2*S*,9*a**S**R*)-9a-butyl-2-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*S*,9*a**S**R*)-9a-butyl-7-hydroxy-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*S*,9*a**S**R*)-9a-butyl-7-hydroxy-4-methyl-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

C
C
Cont'd

(2*S*,9a*S**R*)-4,9a-dibutyl-7-hydroxy-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*S*,9a*S**R*)-4-bromo-9a-butyl-7-hydroxy-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*RS*,9a*S**R*)-9a-butyl-7-hydroxy-2-(2-oxoethyl)-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*S*,9a*S**R*)-2,9a-dibutyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*RS*,9a*RS*)-9a-butyl-7-hydroxy-2,4-dimethyl-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-2,2-dipropyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-7-hydroxy-4-methyl-2,2-dipropyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*SR*,9a*RS*)-9a-butyl-2,7-dihydroxy-4-methyl-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4-bromo-9a-butyl-2,2-diethyl-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*SR*,9a*S**R*)-7-hydroxy-2,4,9a-trimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*SR*,9a*S**R*)-7-hydroxy-4,9a-dimethyl-2-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

(2*SR*,9a*S**R*)-9a-butyl-8-chloro-2-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

8-chloro-9a-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

C
Cont'd

8-bromo-9a-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-ethyl-7-hydroxy-4,8-dimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
8-chloro-7-hydroxy-4-methyl-9a-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
8-bromo-7-hydroxy-4-methyl-9a-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
7-hydroxy-4,8-dimethyl-9a-propyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
8-chloro-7-hydroxy-4-methyl-9a-[(1*E*)-1-propenyl]-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
8-bromo-9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-7-hydroxy-4,8-dimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-7-hydroxy-4-methyl-8-nitro-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
8-amino-9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-7-hydroxy-4-(4-hydroxyphenyl)-8-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-7-hydroxy-8-methyl-4-{4-[2-piperidinyl]-ethoxy}phenyl}-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
4-bromo-7-hydroxy-9a-propyl-1*H*-fluorene-3,9(2*H*,9a*H*)-dione;
4,8-dibromo-7-hydroxy-9a-propyl-1*H*-fluorene-3,9(2*H*,9a*H*)-dione;
4-bromo-9a-butyl-7-hydroxy-6-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;
9a-butyl-8-chloro-4-methyl-3-oxo-2,3,9,9a-tetrahydro-1*H*-fluoren-7-yl pivalate;

Confidential

9a-butyl-6,8-difluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4-ethyl-6,8-difluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4-bromo-9a-butyl-6,8-difluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

8-bromo-9a-butyl-4-chloro-8-difluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-butyl-4,8-dibromo-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6-fluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6,8-difluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

8-chloro-9a-ethyl-6-fluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

8-bromo-9a-ethyl-6-fluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6-fluoro-7-hydroxy-4,8-dimethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4,9a-diethyl-6,8-difluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4-bromo-8-chloro-9a-ethyl-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4-bromo-8-chloro-9a-(cyclopentylmethyl)-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-5-fluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

Confidential

8-bromo-9a-ethyl-5-fluoro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6,7-dihydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

8-bromo-9a-ethyl-6,7-dihydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

9a-ethyl-6-hydroxy-4-vinyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

4-allyl-9a-ethyl-6-hydroxy-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

2-hydroxy-5-methyl-7,8,9,10-tetrahydro-7,10a-methanocycloocta[*a*]inden-6(11*H*)-one;

7-amino-4-bromo-9a-butyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

7-amino-4,8-dibromo-9a-ethyl-1,2,9,9a-tetrahydro-3*H*-fluoren-3-one;

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. (Original) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

8. (Original) A pharmaceutical composition made by combining a compound according to Claim 1 and a pharmaceutically acceptable carrier.

9. (Original) A process for making a pharmaceutical composition comprising combining a compound according to Claim 1 and a pharmaceutically acceptable carrier.

10. (Original) A method of eliciting an estrogen receptor modulating effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

11. (Original) The method according to Claim 10 wherein the estrogen receptor modulation effect is an estrogen receptor antagonizing effect.

12. (Original) The method according to Claim 11 wherein the estrogen receptor antagonizing effect is an ER α receptor antagonizing effect.

13. (Original) The method according to Claim 11 wherein the estrogen receptor antagonizing effect is an ER β receptor antagonizing effect.

14. (Original) The method according to Claim 11 wherein the estrogen receptor antagonizing effect is a mixed ER α and ER β receptor antagonizing effect.

15. (Original) The method according to Claim 10 wherein the estrogen receptor modulation effect is an estrogen receptor agonizing effect.

16. (Original) The method according to Claim 15 wherein the estrogen receptor agonizing effect is an ER α receptor agonizing effect.

17. (Original) The method according to Claim 15 wherein the estrogen receptor agonizing effect is an ER β receptor agonizing effect.

18. (Original) The method according to Claim 15 wherein the estrogen receptor agonizing effect is a mixed ER α and ER β receptor agonizing effect.

19. (Amended) A method of treating or preventing hot flashes in a mammal in need thereof by administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

CONFIDENTIAL

20. (Amended) A method of treating ~~or preventing~~ anxiety in a mammal in need thereof by administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

21. (Amended) A method of treating ~~or preventing~~ depression in a mammal in need thereof by administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

22. (Previously Added) The compound of Claim 6 which is 9a-ethyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

23. (Previously Added) The compound of Claim 6 which is 9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

24. (Previously Added) The compound of Claim 6 which is 4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

25. (Previously Added) The compound of Claim 6 which is 9a-butyl-8-chloro-7-hydroxy-4-methyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

26. (Previously Added) The compound of Claim 6 which is 9a-butyl-8-chloro-4-cyano-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

27. (Previously Added) The compound of Claim 6 which is 9a-ethyl-6-fluoro-7-hydroxy-4,8-dimethyl-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

Cont'd

28. (Previously Added) The compound of Claim 6 which is 4-bromo-8-chloro-9a-ethyl-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

29. (Previously Added) The compound of Claim 6 which is 4-bromo-9a-butyl-8-chloro-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

30. (Previously Added) The compound of Claim 6 which is 9a-butyl-8-chloro-6-fluoro-7-hydroxy-4-(trifluoromethyl)-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

31. (Previously Added) The compound of Claim 6 which is 4-bromo-8-chloro-9a-(cyclopentylmethyl)-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one or a pharmaceutically acceptable salt or stereoisomer thereof.

32. (New) A pharmaceutical composition comprising a compound of Claim 1 and an organic bisphosphonate or a cathepsin K inhibitor, or a pharmaceutically acceptable salt or mixture thereof.

33. (New) The composition of Claim 32 wherein the bisphosphonate is selected from alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts, esters or mixtures thereof.

34. (New) The composition of Claim 33 wherein the bisphosphonate is alendronate.

35. (New) A method of treating hot flashes comprising administering to a mammal in need thereof a compound of Claim 1 and an organic bisphosphonate or a cathepsin K inhibitor, or a pharmaceutically acceptable salt or mixture thereof.

*C-1
CONT'D*

36. (New) The method of Claim 35 wherein the bisphosphonate is selected from alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts, esters or mixtures thereof.

37. (New) The method of Claim 36 wherein the bisphosphonate is alendronate.

38. (New) A method of treating depression comprising administering to a mammal in need thereof a compound of Claim 1 and an organic bisphosphonate or a cathepsin K inhibitor, or a pharmaceutically acceptable salt or mixture thereof.

39. (New) The method of Claim 38 wherein the bisphosphonate is selected from alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts, esters or mixtures thereof.

40. (New) The method of Claim 39 wherein the bisphosphonate is alendronate.

Concl